IQVIA Holdings Inc

IQVIA Holdings Inc. boosts earnings with AI‑driven market‑access tools and growing clinical‑trial services, targeting a 45% market share and $1.2 bn 2024 revenue.

IQVIA Holdings Inc. shows how data‑driven platforms—molecular biology, AI, RWE—boost clinical trials and market success, driving growth in the life‑sciences services sector.

IQVIA Holdings: How robust data‑analytics and regulatory savvy keep the life‑sciences tech leader in a strong growth trajectory while navigating emerging DCTs, privacy rules and AI transparency challenges.

IQVIA’s steady rise in a volatile life‑sciences tech market hinges on AI‑powered data integration, patient‑retention analytics, and blockchain‑enabled compliance, driving 6% revenue growth and 24% EBITDA margin toward 2026.

IQVIA refines debt, cuts interest, and faces Belgian regulatory probe—boosting margins and market‑access plans while navigating competition scrutiny.

IQVIA Holdings Inc. stays ahead in health‑care by combining clinical services, real‑world analytics, and patient‑retention tools—leveraging data science to boost drug development, market access, and personalized medicine.

TD Cowen downgrades IQVIA to Hold but lifts its target to $65, reflecting a cautious yet optimistic view amid life‑sciences volatility and macro‑economic risks.

IQVIA Holdings Inc. reports record free-cash flow of $772 million in Q3 FY 2025, driven by AI-driven growth and strategic initiatives, positioning the company for continued success in the life-sciences consulting sector.

IQVIA Holdings Inc has announced a leadership transition, with CFO Ron Bruehlman retiring and being replaced by Michael Fedock, who will take over as CFO in February 2026.

IQVIA Holdings Inc. has formed two significant partnerships with Flagship Pioneering and Veeva, aiming to accelerate breakthroughs and drive innovation in the life sciences industry.